Coeptis Therapeutics' Phase 1 Trials Of DVX201 For Relapsed/Refractory Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome And Hospitalized Covid-19 Patients Showed No Dose-limiting Toxicities, Cytokine Release Syndrome Or Infusion Toxicities
Portfolio Pulse from Benzinga Newsdesk
Coeptis Therapeutics' Phase 1 trials of DVX201 for relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome and hospitalized Covid-19 patients showed no dose-limiting toxicities, cytokine release syndrome or infusion toxicities.
September 14, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coeptis Therapeutics' successful Phase 1 trials of DVX201 could potentially boost the company's stock in the short term.
The successful Phase 1 trials of DVX201 indicate that the drug is safe and well-tolerated, which is a positive sign for the company. This could potentially lead to increased investor confidence and a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100